Cardiome Pharma Corporation (CRME) is a biopharmaceutical company based in Vancouver, Canada. It specializes in developing and commercializing innovative therapies for cardiovascular diseases. The company's primary focus is on the development of Brinavess (vernakalant hydrochloride), a drug used for the treatment of atrial fibrillation.
Brinavess is an intravenous (IV) formulation of vernakalant, a novel antiarrhythmic drug that is designed to rapidly convert recent onset atrial fibrillation to normal sinus rhythm. The drug is approved for use in the European Union and certain other countries, but is not yet approved for use in the United States.
In addition to Brinavess, Cardiome is also developing a pipeline of other cardiovascular therapies, including Trevyent, a drug-device combination product for the treatment of pulmonary arterial hypertension, and an oral formulation of vernakalant for the maintenance of sinus rhythm in atrial fibrillation patients.
Cardiome was founded in 1986 and went public in 2000. The company has collaborations with various pharmaceutical companies and research organizations to develop and commercialize its products.
|
